Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• Executive insider selling: EVP Paul Mahon sold 8,300 United Therapeutics shares for approximately $4.29 million, reducing his holdings by 15.52% to 45,172 shares.
• Mixed quarterly results: United Therapeutics reported adjusted EPS of $7.27, beating estimates of $6.86, but revenue of $783.3 million missed expectations and declined 1.9% year over year.
• Analysts remain broadly positive: The stock has a “Moderate Buy” consensus rating and a $646 average price target, while shares recently traded up 2.7% at $532.94.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $517.05, for a total transaction of $4,291,515.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company's stock, valued at approximately $23,356,182.60. This represents a 15.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Trading Up 2.7%

Shares of United Therapeutics stock traded up $13.93 during trading on Thursday, hitting $532.94. 992,945 shares of the stock were exchanged, compared to its average volume of 490,031. United Therapeutics Corporation has a 1-year low of $292.34 and a 1-year high of $609.35. The stock has a market capitalization of $22.62 billion, a price-to-earnings ratio of 19.67, a price-to-earnings-growth ratio of 1.73 and a beta of 0.59. The company has a fifty day moving average price of $540.37 and a 200-day moving average price of $533.71.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analysts' expectations of $804.65 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics's quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the company posted $6.41 earnings per share. Equities research analysts forecast that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at approximately $159,522,000. Focus Partners Advisor Solutions LLC acquired a new position in United Therapeutics during the 2nd quarter worth approximately $795,000. S&CO Inc. bought a new position in United Therapeutics in the 2nd quarter valued at approximately $775,000. Handelsbanken Fonder AB lifted its stake in United Therapeutics by 4.1% in the 2nd quarter. Handelsbanken Fonder AB now owns 13,120 shares of the biotechnology company's stock valued at $7,109,000 after purchasing an additional 520 shares during the last quarter. Finally, PensionDanmark Pensionsforsikringsaktieselskab boosted its position in United Therapeutics by 7.4% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 11,058 shares of the biotechnology company's stock valued at $5,992,000 after buying an additional 760 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analyst support remained strong. H.C. Wainwright reiterated its Buy rating and maintained a $660 price target, citing United Therapeutics’ diversified pipeline as a counterbalance to near-term headwinds. Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds
• Positive Sentiment: Second-quarter EPS beat expectations. United Therapeutics reported earnings of $7.27 per share, above the roughly $6.82–$6.86 analyst consensus and up from $6.41 a year earlier. The company also posted a 40.62% net margin, supporting the stock’s valuation. United Therapeutics Q2 Earnings Surpass Estimates
• Positive Sentiment: Pipeline developments improved the longer-term outlook. Management highlighted regulatory submissions and continued progress for ralinepag and Tyvaso-related programs. Analysts view these products as potential future growth drivers that could diversify the company beyond its existing pulmonary arterial hypertension therapies. United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Royal Bank of Canada lowered its price target from $704 to $677 but retained an Outperform rating, still implying substantial potential upside from recent trading levels. The reduction signals more cautious near-term assumptions rather than a change to the overall bullish view. Benzinga
• Negative Sentiment: Revenue missed estimates and declined year over year. Second-quarter revenue was $783.3 million, below the $804.65 million consensus and down about 2% from the prior year. Competitive pressure and concerns surrounding Tyvaso are the primary near-term operating headwinds. United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
• Negative Sentiment: CEO Martine Rothblatt sold approximately $4.9 million of stock. The sale reduced her direct holdings by 2.84%, potentially weighing modestly on sentiment, although she continues to own a substantial position. United Therapeutics CEO Stock Sale Filing

Analysts Set New Price Targets

UTHR has been the topic of several research reports. Wells Fargo & Company upgraded shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Bank of America decreased their price target on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Weiss Ratings downgraded shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Friday, July 31st. Raymond James Financial began coverage on United Therapeutics in a research note on Friday, April 10th. They issued an "outperform" rating and a $700.00 price target for the company. Finally, JPMorgan Chase & Co. lifted their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $646.00.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source